MeSH term
Frequency | Condition_Probility | Animals | 9 | 0.0 |
Humans | 32 | 0.0 |
Apoptosis | 5 | 0.0 |
Cell Differentiation | 3 | 0.0 |
Cell Division | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 20 | 0.0 |
Signal Transduction | 3 | 0.0 |
Adolescent | 2 | 0.0 |
Adult | 5 | 0.0 |
Aged | 6 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Disease-Free Survival | 2 | 0.0 |
Female | 9 | 0.0 |
Male | 9 | 0.0 |
Middle Aged | 8 | 0.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Prognosis | 3 | 0.0 |
*Proto-Oncogene Proteins c-bcl-2 | 6 | 1.0 |
Research Support, Non-U.S. Gov't | 14 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
Apoptosis/drug effects | 2 | 0.0 |
Camptothecin/pharmacology | 2 | 4.0 |
Cell Survival/drug effects | 3 | 0.0 |
Etoposide/pharmacology | 3 | 2.0 |
Tumor Cells, Cultured | 10 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Genetic Markers | 3 | 0.0 |
Blotting, Western | 3 | 0.0 |
Mice | 5 | 0.0 |
Mice, Transgenic | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 3 | 0.0 |
*Apoptosis | 4 | 0.0 |
Cell Death | 2 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
In Situ Nick-End Labeling | 2 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/*biosynthesis | 2 | 1.0 |
Up-Regulation | 2 | 0.0 |
Amino Acid Sequence | 3 | 0.0 |
Cell Cycle/*physiology | 2 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Gene Library | 3 | 0.0 |
Molecular Sequence Data | 5 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Protein Binding | 2 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Binding Sites | 2 | 0.0 |
Enzyme Activation | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 3 | 0.0 |
Mitogen-Activated Protein Kinases/*metabolism | 2 | 0.0 |
Neoplasm Proteins/chemistry/*metabolism | 2 | 11.0 |
Okadaic Acid/pharmacology | 2 | 2.0 |
Paclitaxel/pharmacology | 3 | 3.0 |
Phosphorylation | 3 | 0.0 |
Time Factors | 2 | 0.0 |
Transfection | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 4 | 0.0 |
Vinblastine/pharmacology | 2 | 5.0 |
Infusions, Intravenous | 2 | 0.0 |
Treatment Outcome | 2 | 0.0 |
Comparative Study | 5 | 0.0 |
Base Sequence | 3 | 0.0 |
Proto-Oncogene Proteins c-bcl-2/biosynthesis | 2 | 1.0 |
Polymerase Chain Reaction | 2 | 0.0 |
*Chromosome Mapping | 2 | 0.0 |
Consanguinity | 2 | 0.0 |
Genes, Recessive | 2 | 0.0 |
Haplotypes | 2 | 0.0 |
Hybrid Cells | 2 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Bundle-Branch Block/diagnosis/physiopathology | 2 | 100.0 |
Diagnosis, Differential | 2 | 0.0 |
Heart Conduction System/physiopathology | 2 | 11.0 |
Electrodes | 5 | 11.0 |
United States | 2 | 0.0 |
*Chromosomes, Human, Pair 1 | 2 | 0.0 |
*Oncogenes | 2 | 0.0 |
English Abstract | 2 | 0.0 |
*Gene Expression Profiling | 2 | 0.0 |
*Oligonucleotide Array Sequence Analysis | 2 | 1.0 |
Monitoring, Physiologic/methods | 2 | 8.0 |
